Orient Europharma Company Overview
- Year Founded
-
1982
- Status
-
Public
- Employees
-
800
- Stock Symbol
-
4120
- Investments
-
8
- Share Price
-
$1.36
- (As of Thursday Closing)
Orient Europharma Company General Information
Description
Orient Europharma Co Ltd is a Taiwan-based company engaged in the wholesale of Western Pharmaceutical and Medical Devices. The firm also manufactures drugs and medicines, Beverages, Cleaning Preparations, Cosmetics, Medical Devices, and Other Food Products. Its products cover various therapeutic areas, including the central nervous system, cardiovascular, diabetes, allergy, cosmetics, and health supplements. The company's segments include: Western Pharma BU which includes manufacture and sale of pharmaceutical and cosmetic products; and Nutricare BU includes sale of various nutrition supplements and consumable healthcare products. It derives maximum revenue from Western Pharma BU segment. Geographically, it operates in Taiwan, China, and Southeast Asia.
Contact Information
Website
www.oepgroup.comCorporate Office
- 7F, No. 368, Sec 1
- Fu Hsing S. Road
- Taipei, 106
- Taiwan
Corporate Office
- 7F, No. 368, Sec 1
- Fu Hsing S. Road
- Taipei, 106
- Taiwan
Orient Europharma Company Stock Performance
As of 12-Nov-2026, Orient Europharma Company’s stock price is $1.36. Its current market cap is $118M with 86.7M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.36 | $1.36 | $1.24 - $1.54 | $118M | 86.7M | 20.6K | -$0.21 |
Orient Europharma Company Financials Summary
As of 30-Jun-2026, Orient Europharma Company has a trailing 12-month revenue of $150M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 180,506 | 242,983 | 235,352 | |
| Revenue | 149,770 | 147,299 | 136,841 | 147,422 |
| EBITDA | (2,796) | (1,140) | 4,208 | 16,943 |
| Net Income | (18,540) | (18,188) | (8,848) | 4,621 |
| Total Assets | 368,395 | 390,357 | 351,852 | 351,855 |
| Total Debt | 110,540 | 104,543 | 128,685 | 157,591 |
Orient Europharma Company Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Orient Europharma Company Patents
Orient Europharma Company Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3771462-A1 | Cosmetic compositions to prevent and/or ameliorate skin aging and methods of applications | Active | 29-Jul-2019 | ||
| EP-3771462-B1 | Cosmetic compositions to prevent and/or ameliorate skin aging and methods of applications | Active | 29-Jul-2019 | ||
| US-11452681-B2 | Cosmetic compositions to prevent and/or ameliorate skin aging and methods of applications | Active | 29-Jul-2019 | ||
| US-20210030655-A1 | Cosmetic compositions to prevent and/or ameliorate skin aging and methods of applications | Active | 29-Jul-2019 | ||
| AU-2014201696-A1 | Therapeutic methods and compositions for treating diabetes | Inactive | 20-Mar-2014 |
Orient Europharma Company Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Orient Europharma Company Investments (8)
Orient Europharma Company’s most recent deal was a Early Stage VC with Vernus AI for . The deal was made on 04-May-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Vernus AI | 04-May-2026 | Early Stage VC | Other Healthcare Technology Systems | ||
| Rakuten Medical | 13-Apr-2026 | Later Stage VC | Drug Discovery | ||
| Novascope | 26-Aug-2025 | Early Stage VC | Diagnostic Equipment | ||
| Cambium Oncology | 13-Jan-2025 | Later Stage VC | Drug Discovery | ||
| Cambium Bio | 28-Jun-2024 | PIPE | Drug Discovery |
Orient Europharma Company ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Orient Europharma Company Exits (2)
Orient Europharma Company’s most recent exit was on 09-Feb-2022 from Quantum Genomics. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Quantum Genomics | 09-Feb-2022 | Completed |
|
||
| Caliway Biopharmaceuticals | 01-Sep-2021 | Later Stage VC | Completed |
|
Orient Europharma Company FAQs
-
When was Orient Europharma Company founded?
Orient Europharma Company was founded in 1982.
-
Where is Orient Europharma Company headquartered?
Orient Europharma Company is headquartered in Taipei, Taiwan.
-
What is the size of Orient Europharma Company?
Orient Europharma Company has 800 total employees.
-
What industry is Orient Europharma Company in?
Orient Europharma Company’s primary industry is Pharmaceuticals.
-
Is Orient Europharma Company a private or public company?
Orient Europharma Company is a Public company.
-
What is Orient Europharma Company’s stock symbol?
The ticker symbol for Orient Europharma Company is 4120.
-
What is the current stock price of Orient Europharma Company?
As of 12-Nov-2026 the stock price of Orient Europharma Company is $1.36.
-
What is the current market cap of Orient Europharma Company?
The current market capitalization of Orient Europharma Company is $118M.
-
What is Orient Europharma Company’s current revenue?
The trailing twelve month revenue for Orient Europharma Company is $150M.
-
What is Orient Europharma Company’s annual earnings per share (EPS)?
Orient Europharma Company’s EPS for 12 months was -$0.21.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
